Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received the drug registration certificate for Baclofen tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for muscle spasms associated with multiple sclerosis [1]. Group 1 - The drug Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis [1]. - The medication may also show efficacy for spasms resulting from infectious, degenerative, traumatic, tumor-related, or unexplained spinal cord diseases [1].

浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于巴氯芬片的《药品注册证书》。现将相关情况 公告如下： 一、药品情况 | 药品名称 | 巴氯芬片 | | | | | --- | --- | --- | --- | --- | | 英文名 | Baclofen | Tablets | | | | 剂型 | 片剂 | | | | | 规格 | 10mg | | | | | 是否处方药 | 是 | | | | | 申请事项 | | 药品注册（境内生产） | | | | 注册分类 | 化学药品 | 类 4 | | | | 药品批准文号 | 国药准字 | | H20263133 | | | 药品批准文号有效期 | 至 2031 | 年 月 1 | 13 | 日 | 1、药品基本情况 证券代码：300702 证券简称：天宇股份 公告编号：2026-004 浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的 ...

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Baclofen tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for muscle spasms associated with multiple sclerosis [1] Group 1 - The drug Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis [1] - Baclofen may also have certain efficacy for spasms resulting from infectious, degenerative, traumatic, tumor-related, or unexplained spinal cord diseases [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Baclofen tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for muscle spasms associated with multiple sclerosis [1] Group 1 - The drug Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis [1] - Baclofen may also have certain efficacy for spasms resulting from infectious, degenerative, traumatic, tumor-related, or unexplained spinal cord diseases [1]

Group 1 - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has received the "High-tech Enterprise Certificate" from the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [2] - Following the recognition as a high-tech enterprise, Jingsheng Pharmaceutical will enjoy tax incentives for three consecutive years (2025 to 2027), paying a corporate income tax rate of 15% as per national regulations [2]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd. (referred to as "Jingsheng Pharmaceutical"), has recently received the "High-tech Enterprise Certificate" issued by the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1] Group 1 - Jingsheng Pharmaceutical will enjoy tax incentives as a high-tech enterprise, specifically a corporate income tax rate of 15% for three consecutive years from 2025 to 2027 [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd. (referred to as "Jingsheng Pharmaceutical"), has recently received the "High-tech Enterprise Certificate" issued by the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1] Group 1 - Jingsheng Pharmaceutical will enjoy tax incentives as a high-tech enterprise, specifically a corporate income tax rate of 15% for three consecutive years from 2025 to 2027 [1]

证券代码：300702 证券简称：天宇股份 公告编号：2026-003 关于全资子公司首次通过高新技术企业认定的公告 特此公告。 浙江天宇药业股份有限公司董事会 二〇二六年一月二十日 浙江天宇药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江京圣药业 有限公司（以下简称"京圣药业"）于近日收到了由浙江省经济和信息化厅、浙 江省财政厅、国家税务总局浙江省税务局联合颁发的《高新技术企业证书》，具 体情况如下： | 企业名称 | 证书编号 | | 发证时间 | | | 有效期 | | --- | --- | --- | --- | --- | --- | --- | | 浙江京圣药业有限公司 | GR202533002271 | 2025 | 年 12 | 月 | 日 19 | 三年 | 根据国家有关规定，京圣药业自通过高新技术企业认定后连续三年（2025 年至 2027 年）享受国家关于高新技术企业的税收优惠政策，即按 15%的税率缴 纳企业所得税。 本次 ...

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration (NMPA) for the active pharmaceutical ingredient (API) Apalutamide, which is used in prostate cancer treatment [1] Group 1: Company Information - Tianyu Co., Ltd. has a subsidiary named Zhejiang Jingsheng Pharmaceutical Co., Ltd. that specializes in pharmaceutical production [1] - The company is focused on developing Apalutamide, a non-steroidal anti-androgen drug [1] Group 2: Product Details - Apalutamide is indicated for the treatment of prostate cancer, specifically non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer [1] - The drug works by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression [1] - Apalutamide is intended to be used in conjunction with androgen deprivation therapy under medical supervision [1]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation for its active pharmaceutical ingredient, Apalutamide, which is used in the treatment of prostate cancer [1] Group 1 - Apalutamide is a non-steroidal anti-androgen drug that works by inhibiting the androgen receptor signaling pathway to delay disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) [1] - Apalutamide is to be used in conjunction with castration therapy under medical guidance [1]